Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Miconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | ALPL | P05186 | 1/20 | 1.00 |
| ▸ | IDO1 | P14902 | 11/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Miconazole SCHEMBL21359032 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAMEN1KMT2ATDP1 | |
| Miconazole SCHEMBL15799 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAMEN1KMT2ATDP1 | |
| (R)-Miconazole SCHEMBL15800 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAMEN1KMT2ATDP1 | |
| Miconazole SCHEMBL8014818 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAMEN1KMT2ATDP1 | |
| Miconazole SCHEMBL8178405 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAMEN1KMT2ATDP1 | |
| Miconazole SCHEMBL8012623 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAMEN1KMT2ATDP1 | |
| Miconazole SCHEMBL8160353 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAMEN1KMT2ATDP1 | |
| Miconazole SCHEMBL8200081 | 0.95 | CYP3A4 (0.91) | CYP3A4LMNAMEN1KMT2ATDP1 | |
| Miconazole SCHEMBL9954418 | 0.95 | CYP3A4 (0.90) | CYP3A4LMNAMEN1KMT2ATDP1 | |
| Miconazole SCHEMBL9662051 | 0.92 | IDO1 (1.00) | CYP3A4LMNAMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2026-03-31 | — | — | US | disclosed |
| US-20250345308-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | ANSELLA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4615528-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED RELEASE OF THERAPEUTIC AGENTS FROM ARTICLES | Kalm Therapeutics Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12329743-B2 | Compositions against Candida infections | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-06-17 | — | — | US | disclosed |
| CN-120131535-A | Miconazole nitrate emulsifiable paste and preparation process thereof | 百草堂医药股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250144066-A1 | Prevention and Treatment of Parasitic Infections | BARANOWITZ STEVEN (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2025064458-A1 | PREVENTION AND TREATMENT OF VIRAL INFECTIONS | BARANOWITZ STEVEN (US) | 2025-03-27 | — | — | WO | disclosed |
| US-12226392-B2 | Prevention and treatment of viral infections | BARANOWITZ STEVEN (US) | 2025-02-18 | — | — | US | disclosed |
| US-12201607-B2 | Compositions and methods for preventing and treating conditions | Ansella Therapeutics, Inc. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-2916820-B1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | ROCHAL TECH LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3949962-B1 | COMPOSITIONS AGAINST CANDIDA INFECTIONS | UNIV LEUVEN KATH (BE) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023157024-A1 | VAGINAL PHARMACEUTICAL COMPOSITION COMPRISING MICONAZOLE AND LULICONAZOLE OR SALTS THEREOF | ZENVISION PHARMA LLP (IN) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023148316-A1 | MAGNESIUM DIACETATE X 4H 2O AND/OR MAGNESIUM DICHLORIDE X 6H 2O AND/OR MAGNESIUM SULFATE X 7H 2O AND/OR DISODIUM SULFATE X 10 H 2O AND/OR SODIUM THIOSULFATE X 5H 2O AND/OR NA 3PO 4 X 12 H 2O AND/OR NA 2HPO 4 X 12H 2O/7H 2O AND/OR SODIUM ACETATE X 3H 2O AS GRANULATING AID | BASF SE (DE) | 2023-08-10 | — | — | WO | disclosed |
| CN-116509869-A | Treatment of extrapyramidal syndrome with trapidil | 希诺皮亚生物科学公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-115845069-A | Combined medicine for treating oral squamous carcinoma, application and kit | 四川大学 | 2023-03-28 | — | — | CN | disclosed |
| US-11590099-B2 | Prevention and treatment of viral infections | BARANOWITZ STEVEN (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2022172285-A1 | NEEM SEED OIL BASED VAGINAL CAPSULE FOR TREATMENT OF ABNORMAL VAGINAL DISCHARGE | NUTRA GRACE (IN) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022162078-A1 | COMPOSITION FOR USE IN DEGRADATION OF BIOFILM OR PREVENTION OF BIOFILM FORMATION | PHARMIVA AB (SE) | 2022-08-04 | — | — | WO | disclosed |
| EP-3949962-A1 | COMPOSITIONS AGAINST CANDIDA INFECTIONS | Katholieke Universiteit Leuven (BE) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201607-B2 | Compositions and methods for preventing and treating conditions | LIPA, COL2A1, COL1A1 | CYP3A4 4807/4885LMNA 43/4885MEN1 1247/4885 |
| US-20250144066-A1 | Prevention and Treatment of Parasitic Infections | EPX, CTSA, SERPINB1 | CYP3A4 598/4885LMNA 2810/4885MEN1 2783/4885 |
| US-12226392-B2 | Prevention and treatment of viral infections | MAVS, HAVCR2, MTREX | CYP3A4 2431/4885LMNA 2301/4885MEN1 3629/4885 |
| US-11590099-B2 | Prevention and treatment of viral infections | MAVS, HAVCR2, ZC3HAV1 | CYP3A4 3103/4885LMNA 3448/4885MEN1 1615/4885 |
| US-20250345308-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | LIPA, COL2A1, COL1A1 | CYP3A4 4807/4885LMNA 43/4885MEN1 1247/4885 |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TPM4, TPM3, TAGLN2 | CYP3A4 171/4885LMNA 584/4885MEN1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.